| Document Date: 2011-08-15 11:58:29
Open Document File Size: 72,06 KBShare Result on Facebook
City SEATTLE / / Company HemaQuest Pharmaceuticals / / Country United States / / Event FDA Phase / / IndustryTerm biopharmaceutical / cancer therapies / fatty acid technologies / short chain / treatment of lymphomas and related cancers / / MedicalCondition cancers / tumor / related cancers / cancer / lymphoma / nasopharyngeal carcinoma / post‐transplant lymphoproliferative disorders / common hemoglobin disorders / viral‐infected tumor / refractory EBV‐related lymphomas / lymphoid cancers / solid tumors / hematologic malignancies / beta thalassemia intermedia / lymphomas / stomach cancer / hematologic diseases / sickle cell disease / infection / beta thalassemia / Currently available cancer / complete tumor responses / objective tumor / similar cancers / viral‐related cancers / / MedicalTreatment immunosuppressive therapy / cancer therapies / chemotherapy / antiviral therapy / / Organization FDA / / Person Susan Perrine / BARR VIRUS MALIGNANCIES EBV / Ronald Berenson / / Position President and Chief Executive Officer / forward in the development / Chief Scientific Officer and VP of Clinical Affairs / / Product Ganciclovir / HQK / EBV‐Related Malignancies SEATTLE / / Technology chemotherapy / fatty acid technologies / / URL www.HemaQuest.com / /
SocialTag |
Microsoft Word - Final - HemaQuest Pharmaceuticals Initiates Clinical Trial in EBV-Related Malignancies _8-11-2010_